Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBXA2R | P21731 | 13/20 | 0.81 |
| ▸ | PTGDR | Q13258 | 3/20 | 0.54 |
| ▸ | PTGDR2 | Q9Y5Y4 | 3/20 | 0.54 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.54 |
| ▸ | DRD1 | P21728 | 1/20 | 0.54 |
| ▸ | CCKAR | P32238 | 1/20 | 0.54 |
| ▸ | TBXAS1 | P24557 | 6/20 | 0.53 |
| ▸ | RB1 | P06400 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9015455 | 0.90 | TBXA2R (0.81) | TBXA2RTBXAS1 | |
| SCHEMBL527812 | 0.90 | TBXA2R (1.00) | TBXA2RTBXAS1 | |
| SCHEMBL15052324 | 0.89 | TBXA2R (0.77) | TBXA2RPTGDRPTGDR2ABCB11CYP2C9 | |
| SCHEMBL15052559 | 0.87 | TBXA2R (0.62) | TBXA2RPTGDRPTGDR2ABCB11CYP2C9 | |
| SCHEMBL15051975 | 0.87 | TBXA2R (0.62) | TBXA2RPTGDRPTGDR2ABCB11CYP2C9 | |
| SCHEMBL9257256 | 0.85 | TBXA2R (0.60) | TBXA2RPTGDRPTGDR2ABCB11CYP2C9 | |
| SCHEMBL15053155 | 0.84 | TBXA2R (0.59) | TBXA2RPTGDRPTGDR2ABCB11CYP2C9 | |
| SCHEMBL15052127 | 0.84 | TBXA2R (0.73) | TBXA2RCYP2C9TBXAS1 | |
| SCHEMBL15052335 | 0.83 | TBXA2R (0.58) | TBXA2RPTGDRPTGDR2ABCB11CYP2C9 | |
| SCHEMBL9247892 | 0.82 | TBXA2R (0.82) | TBXA2RPTGDRPTGDR2ABCB11CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8927586-B2 | Thromboxane A2 (TP) receptor antagonists | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2015-01-06 | — | — | US | disclosed |
| US-20130165488-A1 | Novel Thromboxane A2 (TP) Receptor Antagonists | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2013-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130165488-A1 | Novel Thromboxane A2 (TP) Receptor Antagonists | TBXA2R, TBXAS1, PTGIR | TBXA2R 1/4885PTGDR 5/4885PTGDR2 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.